Azad AA - Search Results

1

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Azad AA, et al. Eur Urol. 2015 Jan;67(1):23-29. doi: 10.1016/j.eururo.2014.06.045. Epub 2014 Jul 10. Eur Urol. 2015. PMID: 25018038

2

Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome?

Azad AA, Eigl BJ. Azad AA, et al. Eur Urol. 2014 Feb;65(2):504-5. doi: 10.1016/j.eururo.2013.10.035. Epub 2013 Nov 1. Eur Urol. 2014. PMID: 24210911 No abstract available.

3

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN. Azad AA, et al. Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31. Eur Urol. 2015. PMID: 24508071

4

A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.

Azad AA, Beardsley EK, Hotte SJ, Ellard SL, Klotz L, Chin J, Kollmannsberger C, Mukherjee SD, Chi KN. Azad AA, et al. Invest New Drugs. 2014 Aug;32(4):746-52. doi: 10.1007/s10637-014-0091-8. Epub 2014 Mar 28. Invest New Drugs. 2014. PMID: 24671507 Clinical Trial.

5

Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.

Azad AA, Jones EC, Chi KN. Azad AA, et al. Clin Genitourin Cancer. 2014 Aug;12(4):e151-3. doi: 10.1016/j.clgc.2014.03.006. Epub 2014 Mar 26. Clin Genitourin Cancer. 2014. PMID: 24787970 No abstract available.

6

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN. Azad AA, et al. Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29. Prostate. 2014. PMID: 25175831

7

Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer.

Zielinski RR, Azad AA, Chi KN, Tyldesely S. Zielinski RR, et al. Among authors: azad aa. Can Urol Assoc J. 2014 Jul;8(7-8):E520-3. doi: 10.5489/cuaj.2076. Can Urol Assoc J. 2014. PMID: 25210555 Free PMC article.

8

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.

Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A. Bishop JL, et al. Among authors: azad aa. Oncotarget. 2015 Jan 1;6(1):234-42. doi: 10.18632/oncotarget.2703. Oncotarget. 2015. PMID: 25428917 Free PMC article.

9

Targeting heat shock proteins in metastatic castration-resistant prostate cancer.

Azad AA, Zoubeidi A, Gleave ME, Chi KN. Azad AA, et al. Nat Rev Urol. 2015 Jan;12(1):26-36. doi: 10.1038/nrurol.2014.320. Epub 2014 Dec 16. Nat Rev Urol. 2015. PMID: 25512207 Review.

10

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN. Azad AA, et al. Clin Cancer Res. 2015 May 15;21(10):2315-24. doi: 10.1158/1078-0432.CCR-14-2666. Epub 2015 Feb 23. Clin Cancer Res. 2015. PMID: 25712683

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

186 results

Search Page

Filters